HK1079220A1 - Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases cd83 - Google Patents
Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases cd83Info
- Publication number
- HK1079220A1 HK1079220A1 HK05111319.6A HK05111319A HK1079220A1 HK 1079220 A1 HK1079220 A1 HK 1079220A1 HK 05111319 A HK05111319 A HK 05111319A HK 1079220 A1 HK1079220 A1 HK 1079220A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- diseases
- prevention
- treatment
- nucleic acids
- acids encoding
- Prior art date
Links
- 230000006806 disease prevention Effects 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02025851A EP1422241A1 (en) | 2002-11-19 | 2002-11-19 | Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases |
PCT/EP2003/012941 WO2004046182A2 (en) | 2002-11-19 | 2003-11-19 | Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1079220A1 true HK1079220A1 (en) | 2006-03-31 |
Family
ID=32187165
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05111319.6A HK1079220A1 (en) | 2002-11-19 | 2005-12-09 | Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases cd83 |
HK14107931.1A HK1194400A1 (zh) | 2002-11-19 | 2014-08-04 | 編碼 可溶形式的核酸 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14107931.1A HK1194400A1 (zh) | 2002-11-19 | 2014-08-04 | 編碼 可溶形式的核酸 |
Country Status (10)
Country | Link |
---|---|
US (3) | US7893200B2 (xx) |
EP (5) | EP1422241A1 (xx) |
JP (3) | JP4740595B2 (xx) |
AU (1) | AU2003292045A1 (xx) |
CA (2) | CA2847795C (xx) |
DK (1) | DK1562985T3 (xx) |
ES (2) | ES2413631T3 (xx) |
HK (2) | HK1079220A1 (xx) |
SI (1) | SI1562985T1 (xx) |
WO (1) | WO2004046182A2 (xx) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1422241A1 (en) | 2002-11-19 | 2004-05-26 | Alexander Steinkasserer | Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases |
US7169898B2 (en) | 2002-12-04 | 2007-01-30 | Alexander Steinkasserer | Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells |
US9102726B2 (en) | 2002-12-04 | 2015-08-11 | Argos Therapeutics, Inc. | Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same |
MX2008015395A (es) * | 2006-08-18 | 2008-12-15 | Argos Therapeutics Inc | Uso de cd83 en terapias de combinacion. |
WO2009108341A1 (en) | 2008-02-28 | 2009-09-03 | Argos Therapeutics, Inc. | Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection |
WO2009142759A1 (en) * | 2008-05-23 | 2009-11-26 | Argos Therapeutics, Inc. | Novel soluble cd83 polypeptides, formulations and methods of use |
JP5888728B2 (ja) * | 2009-11-05 | 2016-03-22 | 国立大学法人大阪大学 | 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法 |
CN109320610B (zh) * | 2015-01-27 | 2021-07-27 | 中国科学技术大学先进技术研究院 | 抗人cd83单克隆抗体及其制备、鉴定和应用 |
EP3318577A4 (en) | 2015-06-30 | 2019-01-23 | Osaka University | ANTIPLEXIN A1 AGONIST ANTIBODY |
WO2018085617A1 (en) | 2016-11-07 | 2018-05-11 | Argos Therapeutics, Inc. | Bispecific antibodies that modulate tlr-4 signaling and uses thereof |
GB2573933B (en) | 2017-01-31 | 2022-07-13 | Kimberly Clark Co | Antibacterial composition including benzoic acid ester and methods of inhibiting bacterial growth utilizing the same |
EP3895723A1 (en) | 2020-04-16 | 2021-10-20 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Scd83 for wound healing, hair growth, and skin and hair care |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5316920A (en) | 1992-04-17 | 1994-05-31 | Dana-Faber Cancer Institute, Inc. | Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily |
US5710262A (en) | 1992-04-17 | 1998-01-20 | Dana-Faber Cancer Institute, Inc. | Nucleic acid encoding HB15 polypeptides |
WO1997029781A1 (en) * | 1996-02-15 | 1997-08-21 | Immunex Corporation | Methods and compositions for modulating an immune response |
JP3492999B2 (ja) | 1997-08-26 | 2004-02-03 | ザイモジェネティクス,インコーポレイティド | 脂肪細胞特異的タンパク質の同族体 |
EP1637160A3 (en) | 1999-05-07 | 2006-05-03 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
GB2370273A (en) | 2000-12-20 | 2002-06-26 | Viaxxel Biotech Gmbh | Compounds that affect CD83 expression |
EP1436319A2 (en) * | 2001-10-18 | 2004-07-14 | Zlatko Ademovic | Repetitive motifs from salivary proline rich proteins, mucin and collagen |
US20040185040A1 (en) * | 2001-11-21 | 2004-09-23 | Celltech R & D Limited | Modulating immune responses |
JP2005519586A (ja) | 2001-11-21 | 2005-07-07 | セルテック アール アンド ディー, インコーポレイテッド | Cd83遺伝子産物を利用したサイトカイン・レベルの操作法 |
US6652537B2 (en) | 2001-12-12 | 2003-11-25 | C. R. Bard, Inc. | Articulating stone basket |
US20030219436A1 (en) * | 2002-03-15 | 2003-11-27 | Ledbetter Jeffrey A. | Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein |
AU2002950779A0 (en) | 2002-08-15 | 2002-09-12 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | A method of immunomodulation |
EP1578366A4 (en) * | 2002-10-09 | 2007-12-19 | Tolerrx Inc | MOLECULES PREFERABLY ASSOCIATED WITH EFFECTOR T CELLS OR REGULATORY T CELLS AND METHODS OF USE THEREOF |
EP1422241A1 (en) | 2002-11-19 | 2004-05-26 | Alexander Steinkasserer | Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases |
US9102726B2 (en) | 2002-12-04 | 2015-08-11 | Argos Therapeutics, Inc. | Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same |
US7169898B2 (en) * | 2002-12-04 | 2007-01-30 | Alexander Steinkasserer | Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells |
WO2009142759A1 (en) | 2008-05-23 | 2009-11-26 | Argos Therapeutics, Inc. | Novel soluble cd83 polypeptides, formulations and methods of use |
-
2002
- 2002-11-19 EP EP02025851A patent/EP1422241A1/en not_active Withdrawn
-
2003
- 2003-11-19 EP EP13189881.9A patent/EP2692733B1/en not_active Expired - Lifetime
- 2003-11-19 ES ES10188586T patent/ES2413631T3/es not_active Expired - Lifetime
- 2003-11-19 CA CA2847795A patent/CA2847795C/en not_active Expired - Lifetime
- 2003-11-19 US US10/535,522 patent/US7893200B2/en active Active
- 2003-11-19 ES ES03767573.3T patent/ES2534308T3/es not_active Expired - Lifetime
- 2003-11-19 EP EP10188586A patent/EP2345670B1/en not_active Expired - Lifetime
- 2003-11-19 EP EP15195041.7A patent/EP3031824A1/en not_active Withdrawn
- 2003-11-19 CA CA2507373A patent/CA2507373C/en not_active Expired - Lifetime
- 2003-11-19 DK DK03767573.3T patent/DK1562985T3/da active
- 2003-11-19 JP JP2004552655A patent/JP4740595B2/ja not_active Expired - Lifetime
- 2003-11-19 WO PCT/EP2003/012941 patent/WO2004046182A2/en active Application Filing
- 2003-11-19 AU AU2003292045A patent/AU2003292045A1/en not_active Abandoned
- 2003-11-19 SI SI200332422T patent/SI1562985T1/sl unknown
- 2003-11-19 EP EP03767573.3A patent/EP1562985B1/en not_active Expired - Lifetime
-
2005
- 2005-12-09 HK HK05111319.6A patent/HK1079220A1/xx not_active IP Right Cessation
-
2011
- 2011-01-21 US US13/011,380 patent/US8759505B2/en active Active
- 2011-02-07 JP JP2011023799A patent/JP5557765B2/ja not_active Expired - Lifetime
-
2014
- 2014-04-24 JP JP2014090480A patent/JP5878584B2/ja not_active Expired - Lifetime
- 2014-06-17 US US14/306,712 patent/US9732140B2/en active Active
- 2014-08-04 HK HK14107931.1A patent/HK1194400A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2004046182A3 (en) | 2004-10-14 |
ES2413631T3 (es) | 2013-07-17 |
CA2507373A1 (en) | 2004-06-03 |
US7893200B2 (en) | 2011-02-22 |
US20150065684A1 (en) | 2015-03-05 |
JP2014195455A (ja) | 2014-10-16 |
CA2847795A1 (en) | 2004-06-03 |
US9732140B2 (en) | 2017-08-15 |
EP3031824A1 (en) | 2016-06-15 |
JP2011144177A (ja) | 2011-07-28 |
EP1562985A2 (en) | 2005-08-17 |
US8759505B2 (en) | 2014-06-24 |
JP2006523432A (ja) | 2006-10-19 |
DK1562985T3 (da) | 2015-04-13 |
EP2692733B1 (en) | 2015-11-18 |
JP4740595B2 (ja) | 2011-08-03 |
CA2507373C (en) | 2014-06-10 |
AU2003292045A8 (en) | 2004-06-15 |
WO2004046182A2 (en) | 2004-06-03 |
HK1194400A1 (zh) | 2014-10-17 |
CA2847795C (en) | 2018-05-01 |
EP2345670B1 (en) | 2013-03-20 |
EP2345670A1 (en) | 2011-07-20 |
US20120015890A1 (en) | 2012-01-19 |
EP2692733A1 (en) | 2014-02-05 |
AU2003292045A1 (en) | 2004-06-15 |
SI1562985T1 (sl) | 2015-05-29 |
JP5557765B2 (ja) | 2014-07-23 |
EP1422241A1 (en) | 2004-05-26 |
ES2534308T3 (es) | 2015-04-21 |
JP5878584B2 (ja) | 2016-03-08 |
US20070167607A1 (en) | 2007-07-19 |
EP1562985B1 (en) | 2015-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1079220A1 (en) | Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases cd83 | |
EP1575480A4 (en) | COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM | |
EP1578367A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES | |
EP1572116A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES | |
EP1576137A4 (en) | COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM | |
EP1416961A4 (en) | COMPOSITION AND METHOD FOR THE TREATMENT OF A DISEASE | |
HRP20040906B1 (en) | Bisphosphonic acid for the treatment and prevention of ostreoporosis | |
EP1571968A4 (en) | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS | |
EP1589933A4 (en) | COMPOSITIONS AND METHODS FOR DIETUMOR DIAGNOSIS AND TREATMENT | |
SI1487541T1 (sl) | Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja | |
WO2004024097A9 (en) | Compositions and methods for the treatment of immune related diseases | |
IL165950A0 (en) | Compositions and method for the diagnosis and treatment of tumor | |
EP1578996A4 (en) | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS | |
EP1553912A4 (en) | COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT | |
EP1560593A4 (en) | NEW COMPOSITION AND METHOD FOR THE TREATMENT OF IMMUNE DISEASES | |
EP1575571A4 (en) | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR | |
AU2003225281A8 (en) | Materials and methods for prevention and treatment of rna viral diseases | |
AU2003299378A8 (en) | Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases | |
HRP20030609A2 (en) | Use of il-18 inhibitors for the treatment and/or prevention of heart disease | |
EP1624786A4 (en) | METHOD FOR THE TREATMENT AND PREVENTION OF ILLNESSES OF BIOLOGICAL CHANNELS | |
EP1472273A4 (en) | COMPOSITIONS AND METHODS FOR TREATING IMMUNE DISEASES | |
AU2003213898A1 (en) | Prevention and treatment of mycoplasma-associated diseases | |
AU2003228339A1 (en) | Prevention and treatment of disease using angiogenesis-and/or tumor antigens | |
GB0201025D0 (en) | The treatment of degenerative diseases | |
EP1572130A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNEAL DISEASES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20231118 |